OOIR: Observatory of International Research

Papers

(The H4-Index of Digestive and Liver Disease is 32. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-06-01 to 2026-06-01.)

Article	Citations
Beyond inflammation: Expanding the horizon on vascular risk assessment in inflammatory	74
Comment on ``Clinical characteristics of immune checkpoint inhibitor-related pancreatic injury with pancreatitis in patients with advanced malignancies''	72
Relationship between recipient/donor features and liver stiffness measurement in the first year after liver transplantation	71
Mapping the hepatic mtDNA genomic landscape in patients with MASLD: The Era of GPT-4 Artificial Intelligence	67
Identification of causes and patterns of albumin structural damages in commercial formulations	60
Assessment of sarcopenia with ultrasound-based measurements in patients with liver cirrhosis and correlation with clinical outcomes	55
Cardiometabolic risk factors and clinical course of liver cirrhosis	53
Full Title Page /Editorial Board	52
Comment on ``Dietary lipophilic index and odds of metabolic dysfunction-associated steatotic liver disease (MASLD): A population-based survey''	49
Association between remnant cholesterol and metabolic dysfunction-associated steatotic liver disease in the elderly	49
Letter to the editor: Comment on “Synergistic effect of oral exclusive enteral nutrition and biologic in induction therapy for adult Crohn disease”	48
Renal cell carcinoma metastasis as an atypical cause of gastrointestinal bleeding	46
OC.04.7 EFFECT OF MTOR INHIBITION ON EXOSOMES ISOLATED FROMPC CELLS WITH DIFFERENT KRAS MUTATIONS	42
OC.22.3 THREE-YEAR OUTCOMES OF ENDOSCOPIC SLEEVE GASTROPLASTY BY OBESITY CLASS	41
OC.09.5 ADVANCING IN ERCP: THE SLIM DUODENOSCOPE AS A CORNERSTONE FOR CHALLENGING ANATOMIES – INSIGHTS FROM AN ITALIAN CASE SERIES	41
OC.09.9 BALANCING RISKS AND BENEFITS: EVALUATING THE SAFETYAND EFFICACY OF CHOLANGIOPANCREATOSCOPY IN ELDERLY AND FRAIL POPULATIONS	39
T.03.5 EVALUATION OF RECTALWALL THICKNESS MEASUREMENT SENSITIVITY VIA TRANSABDOMINAL ULTRASOUND TO ASSESS MUCOSAL ACTIVITY IN ULCERATIVE COLITIS: COULD THIS BE A USEFUL NON-INVASIVE TOOL? A PRELIMINAR	38
OC.17.5 ENDOSCOPIC VACUUM THERAPY (EVT) FOR THE MANAGEMENT OF UPPER GASTROINTESTINAL TRACT LEAKS AND DEFECTS: A RETROSPECTIVE STUDY FROM ATERTIARY REFERRAL CENTER IN NEARLY 100 PATIENTS	38
T.08.4 PRELIMINARY DATA FROM AN ONGOING MULTICENTER STUDY: EVALUATION OF THE DIAGNOSTIC ACCURACY OF CHATGPT-4 IN THE RECOGNITION AND CLASSIFICATION OF ESOPHAGEAL VARICES	38
T.10.4 APULIAN NETWORK FOR INFLAMMATORY BOWEL DISEASE (AN-IBD) SAFETY PROFILE: PILOT DATA	38
Ileocaecal Crohn's disease. To resect or not to resect, is that the question?	36
Other than Insulin Antidiabetic Treatment Associates with Better Status of Frailty in Patients with Cirrhosis and Type 2 Diabetes on Waiting List for Liver Transplantation	36
Gaining knowledge for the choice and use of systemic therapies in the treatment of hepatocellular carcinoma also requires real life and investigators conducted observational studies	34
How macronutrients and pancreatic enzyme supplements dose variability affect fat, protein and starch absorption in children with cystic fibrosis	34
OC.04.1 SURGERY IN HIGH-RISK PAEDIATRIC CROHN'S DISEASE TREATED WITH UP-FRONT ANTI-TNF AGENTS AND LONG-STANDING BIOLOGIC THERAPY	34

Liver transplantation following HCC rupture and long-term immunotherapy: a case report	34
OC.06.4 DEMOGRAPHIC DIFFERENCES IN LEFT-TO-RIGHT SHIFT OF COLON CANCER OVER 25 YEARS: RESULTS FROM ROBUST ANALYSIS OF CANCER REGISTRY DATA	34
Impact of laparoscopic liver resection for access to the waiting list of a single regional liver transplant center in southern Italy: entry and dropout flows’ analysis	33
Impact of ISO score on oncological outcomes and survival in liver transplant candidates with hepatocellular carcinoma	33
Fully automated approach of machine learning combined with deep learning: How to predict the onset of major cardiovascular events in NAFLD patients	33
T.04.5: COMPARISON OF SUBCUTANEOUS AND INTRAVENOUS INFLIXIMAB IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE SHOWED NO DIFFERENCES IN IMMUNOGENICITY OR TREATMENT PERSISTENCE AT ONE YEAR	32
Characteristics and management of hepatocellular carcinoma (HCC) in Sicily: first results of the HCC Sicily Multidisciplinary Network	32
T.12.2: THE LEVELS OF AFP, PIVKA-II AND GPC-3 SERUM BIOMARKERS AT DIAGNOSIS CORRELATE WITH HCC CLINICAL-PATHOLOGICAL FEATURES AND WITH OVERALL SURVIVAL	32
Application of Machine Learning Model-3P to Predict Portal Hypertension in Patient with Hepatocellular Carcinoma	32